Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Other Non-Current Liabilities of $431000.0 for Q1 2026, up 19.72% year-over-year from $360000.0 in Q1 2025, and little changed quarter-over-quarter from $431000.0 in Q4 2025.
Powered by 
Analysis
Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $431000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 19.72% year-over-year to $431000.0; the TTM figure through Mar 2026 stood at $431000.0 (up 19.72% YoY), while the FY2025 annual figure was $431000.0, down 24.39% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $431000.0, roughly flat from $431000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $849000.0 in Q4 2023, with the low at $12000.0 in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $360000.0 (2025), against an average of $359333.3.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 67.24% in 2022, then surged 85.57% in 2025.
- Arcutis Biotherapeutics' Other Non-Current Liabilities stood at $12000.0 in 2022, then soared by 6975.0% to $849000.0 in 2023, then slumped by 32.86% to $570000.0 in 2024, then declined by 24.39% to $431000.0 in 2025, then changed by 0.0% to $431000.0 in 2026.
- Business Quant data shows ARQT's Other Non-Current Liabilities at $431000.0 in Q1 2026, $431000.0 in Q4 2025, and $360000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 431,000.00 |
| Mar 31, 2026 | 431,000.00 |
| Dec 31, 2025 | 431,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Dec 31, 2024 | 570,000.00 |
| Sep 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 194,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Dec 31, 2023 | 849,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 25,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 25,000.00 |
| Mar 31, 2021 | 58,000.00 |
| Dec 31, 2020 | 82,000.00 |
| Sep 30, 2020 | 113,000.00 |
| Jun 30, 2020 | 156,000.00 |